Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study.

Di Scala, Lilla; Bacchi, Marisa; Bayer, Bjørn; Turricchia, Stefano

Di Scala, Lilla; Bacchi, Marisa; Bayer, Bjørn; Turricchia, Stefano.

Affiliation

Di Scala L; Market Access, Janssen, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland. ldiscala@its.jnj.com.
Bacchi M; Statistics and Decision Sciences, Global Development, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.
Bayer B; Global Market Access and Pricing, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.
Turricchia S; Global Medical Affairs, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.

Adv Ther ; 39(9): 4346-4358, 2022 09.

Article in En | MEDLINE | ID: mdl-35917059

Subject(s)

Pulmonary Arterial Hypertension; Pyrimidines; Sulfonamides; Humans; Pulmonary Arterial Hypertension/drug therapy; Pyrimidines/therapeutic use; Sulfonamides/therapeutic use; Treatment Outcome

Key words

Clinical trials; Inverse probability of censoring weighted; Macitentan; Mathematical models; Mortality; Pulmonary arterial hypertension; Rank-preserving structural failure time; Treatment switch

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Pulmonary Arterial Hypertension Type of study: Clinical_trials Limits: Humans Language: En Journal: Adv Ther Journal subject: TERAPEUTICA Year: 2022 Type: Article Affiliation country: Switzerland

Fulltext

XML

PubMed Links

Search on Google